VANCOUVER, BC / ACCESSWIRE / March 4, 2020 / EMPOWER CLINICS INC. (CBDT.CN) (EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company, is pleased to announce that patient visits in corporate clinics increased by 800% in February 2020 versus the same period in 2019, with total patient visits of 1,817 in February 2020 compared to 227 in February 2019.
“Patient volumes have remained strong to start the year in all clinics, continuing on our push for a record first quarter.” said Dustin Klein, SVP Business Development and Director of Empower. “Operational excellence each day, combined with exemplary care for the patient, sets us apart in the markets we serve.”
The Company also has received numerous inquiries with both positive and supportive sentiment, after the recent announcement of the Company’s intention to create a psilocybin and psychedelics division.
“Getting positive reinforcement from researchers, physicians, advocates and practitioners about our intention to enter this developing field of study, gives me confidence that we have made the correct decision to leverage our corporate assets for psilocybin and psychedelics research and development.” said Steven McAuley, Chairman & CEO of Empower.
ABOUT EMPOWER
Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors: Steven McAuley
CEO
604-789-2146
Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/578982/Empower-Clinics-Announces-Significant-Patient-Growth-in-February-2020-with-Visits-Increasing-by-800